Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV.

Pharmaceutics · 2024 · PMC11125931 · PMID 38794258

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an expected trendno p-value reported

The CL was notably slower for LS variants compared to parental variants, an expected trend for the LS mutation.

also in 179 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.